Dose Insider / Glossary / Cagrilintide

CagrilintideWhat it is and what its trials showed

Updated November 20, 2026 · 3 min read · Lau 2021 and Enebo 2021 (Lancet), REDEFINE 1 (NEJM 2025)

Cagrilintide is an experimental, long-acting copy of the hormone amylin, developed by Novo Nordisk and injected once a week. Amylin is released with insulin after meals and promotes fullness, so cagrilintide is studied as a weight medicine, both alone and combined with semaglutide in CagriSema.

10.8%Cagrilintide 4.5 mg, weight lost by week 26
Weight lost by week 26Cagrilintide alone, phase 2, % of weightCagrilintide 4.5 mg10.8%Cagrilintide 0.3 mg6.0%Liraglutide 3 mg9.0%Placebo3.0%Weight lost by week 26Cagrilintide alone, phase 2, % of weightCagrilintide 4.5 mg10.8%Cagrilintide 0.3 mg6.0%Liraglutide 3 mg9.0%Placebo3.0%

706 adults without diabetes; funded by Novo Nordisk.

On this page

In a 26-week trial of cagrilintide alone, weight fell by up to 10.8% on the highest dose, against 3.0% on placebo.1 We found no label for it on DailyMed on November 20, 2026.2

What it is

The trial report describes natural amylin as a pancreatic hormone that induces satiety, and cagrilintide as a long-acting analog of it.1 The Symlin label explains what amylin does: it slows stomach emptying without changing how much food is absorbed, suppresses glucagon and regulates food intake through the brain.3 Pramlintide, the older amylin medicine sold as Symlin, is injected with meals; cagrilintide is built to last much longer. In an early trial its half-life was 159 to 195 hours, close to a week, and its level peaked 24 to 72 hours after an injection, with exposure rising in proportion to the dose.4 A 2025 review adds that people with diabetes are short of their own amylin, which is part of the case for replacing it.5

On its own

The 2021 phase 2 trial enrolled 706 adults without diabetes with a body mass index of 30 or more, or 27 or more with high blood pressure or high cholesterol. They took cagrilintide at one of several doses from 0.3 mg to 4.5 mg, liraglutide 3 mg, or placebo, once a week for 26 weeks, except liraglutide, which is daily.1

The trial ran at 57 sites in ten countries, including the United States, Canada, Japan and the United Kingdom. Its authors concluded that cagrilintide lowered weight and was well tolerated, and that the results supported developing weight medicines with new mechanisms. The trial was funded by Novo Nordisk.1

With semaglutide

Cagrilintide's main future is as a partner. In a 20-week phase 1b trial in 96 adults, adding cagrilintide 2.4 mg to semaglutide 2.4 mg lowered weight by 17.1%, against 9.8% on semaglutide with placebo. Cagrilintide did not change how semaglutide was absorbed or cleared.4 In the 68-week REDEFINE 1 trial, the combination, called CagriSema, lowered weight by 20.4% against 3.0% on placebo in 3,417 adults without diabetes.6

Side effects

In the phase 2 trial, stomach and gut events were reported by 41% to 63% on cagrilintide against 32% on placebo, mainly nausea, at 20% to 47% against 18%. Reactions at the injection site were also among the most frequent events. The wide range for nausea, from 20% in one dose group to 47% in another, shows how much the rate varied across the doses tested.1 With semaglutide added, as in REDEFINE 1, stomach and gut events rose to 79.6% against 39.9% on placebo, mostly short-lived and mild to moderate.6

Why it matters

On its own, cagrilintide did slightly better than liraglutide 3 mg over 26 weeks, the only GLP-1 medicine it was compared with directly in the trials we read.1 Its value will be judged on the combination: whether CagriSema adds enough to semaglutide to justify a second drug in the same weekly shot. Our page on Ozempic and Wegovy covers semaglutide itself.

Sources

  1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160-2172. Funded by Novo Nordisk. doi:10.1016/S0140-6736(21)01751-7
  2. DailyMed, U.S. National Library of Medicine. Search for "cagrilintide", no results; read November 20, 2026. dailymed.nlm.nih.gov
  3. SYMLINPEN (pramlintide acetate) injection prescribing information. AstraZeneca; DailyMed, version published August 20, 2024; sections 1, 2 and 12.1. dailymed.nlm.nih.gov
  4. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021;397:1736-1748. Funded by Novo Nordisk. doi:10.1016/S0140-6736(21)00845-X
  5. Volčanšek Š, Koceva A, Jensterle M, Janež A, Muzurović E. Amylin: from mode of action to future clinical potential in diabetes and obesity. Diabetes Ther 2025;16:1207-1227. doi:10.1007/s13300-025-01733-8
  6. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med 2025;393:635-647. Funded by Novo Nordisk. doi:10.1056/NEJMoa2502081

Related analyses

Log any GLP-1 medicine you take and see your doses, weight and symptoms together.

Open Dose Insider